ACI
ADMA icon

AMP Capital Investors’s ADMA Biologics ADMA Stock Holding History

AMP Capital Investors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,400
Closed -$102K – 1123
2018
Q3 		$102K Sell
16,400
-7,700
-32% -$44.3K ﹤0.01% 1136
2018
Q2 		$109K Buy
+24,100
New +$120K ﹤0.01% 1154

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AMP Capital Investors's ADMA Position: Q4 2018 in Review

AMP Capital Investors sold out of ADMA Biologics (ADMA) in Q4 2018, closing a stake of 16,400 shares — an estimated $102K sold.

AMP Capital Investors first reported a position in ADMA in Q2 2018 and held it in 2 quarters. The position peaked at $109K in Q2 2018. 52 funds tracked by Wall St. Rank hold ADMA as of Q4 2018.

  • AMP Capital Investors reported no remaining ADMA Biologics position as of Q4 2018 after selling out during the quarter.
  • AMP Capital Investors sold 16,400 ADMA Biologics shares in Q4 2018, an estimated $102K.
  • AMP Capital Investors first reported a position in ADMA Biologics in Q2 2018 and held it in 2 quarters.
  • AMP Capital Investors's ADMA Biologics position peaked at $109K in Q2 2018.
  • 52 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2018.

Based on AMP Capital Investors's 13F filing for Q4 2018, filed 13 Feb 2019.